

# **GUIDELINE**

## **THE INVESTIGATION AND MANAGEMENT OF NEONATAL HAEMOSTASIS AND THROMBOSIS<sup>ψ</sup>**

**M D Williams, Birmingham Children's Hospital, Birmingham.**

**E A Chalmers, Royal Hospital for Sick Children, Yorkhill, Glasgow.**

**B E S Gibson, Royal Hospital for Sick Children, Yorkhill, Glasgow.**

**On behalf of the Haemostasis and Thrombosis Task Force, British Committee for  
Standards in Haematology.**

Correspondence : Michael Williams, Department of Haematology, Birmingham Children's  
Hospital, Steelhouse Lane, Birmingham B4 6NH, UK.

E-mail : [mike.williams@bhamchildrens.wmids.nhs.uk](mailto:mike.williams@bhamchildrens.wmids.nhs.uk)

<sup>ψ</sup> Although the advice and information contained in these guidelines is believed to be true and accurate at the time of going to press, neither the authors nor the publishers can accept any legal responsibility or liability for any errors or omissions.

## **SUMMARY**

These guidelines address developmental aspects of neonatal haemostasis and thrombosis, the laboratory investigation of the neonate and the diagnosis and clinical management of haemostatic and thrombotic conditions occurring in this period (defined as the first four weeks of life following birth). Relevant scientific papers were identified by a systematic literature review from Medline 1975 – 2000 using index terms which incorporated the various component subjects of these guidelines. Further publications were obtained from the references cited and from reviews known to the members of the working party and to the Haemostasis and Thrombosis Task Force. Evidence and graded recommendations presented in these guidelines are in accordance with the US Agency for Health Care Policy and Research (US Department of Health and Human Services, 1992; see Appendix ). It will be noted that there is a lack of a strong evidence base for many of the recommendations suggested as the appropriate clinical and laboratory trials have not been and perhaps never will be undertaken in neonates. Most of the recommendations are therefore of Grade C evidence levels IV : higher levels are mentioned specifically throughout the document where relevant.

## **INTRODUCTION.**

The human haemostatic system is dynamic and is profoundly influenced by age. Although considered immature in the newborn, it is a physiological system which results in few problems for the healthy term neonate, but may contribute to morbidity in the sick and preterm infant when additional acquired abnormalities may be present. Many of the procoagulants, anticoagulants and proteins involved in fibrinolysis are gestation-dependent. The newborn's haemostatic system matures during the early weeks and months of life with most haemostatic parameters reaching adult values by six months of age. In addition there is evidence of an accelerated maturation pattern in the premature infant with preterms showing similar levels of coagulation proteins to term infants by six months of age. Values for coagulation parameters in the infant are therefore dependent to a varying extent on both the gestational and postnatal age of the infant and are shown in Tables 1-6 ( Andrew et al 1987, Andrew et al, 1988). An understanding of these age -related ranges is essential to the interpretation of neonatal investigations.

## **1. INDICATIONS FOR HAEMOSTATIC OR THROMBOTIC TESTING OF THE NEONATE.**

### ***Haemostasis.***

The majority of bleeding problems in the neonatal period are acquired but inherited coagulation disorders may also present at this time especially following iatrogenic challenges. Generally,

testing for defects of haemostasis is indicated in all sick neonates, which would include all admissions to the neonatal intensive care unit. More specifically, screening is carried out in the following circumstances:

- Any haemorrhagic neonate.
- A family history of an inherited bleeding disorder (dependent on the coagulation factor defect, the severity of the deficiency and the likelihood of an accurate diagnosis in the neonate).
- Severe metabolic disease, severe respiratory distress syndrome, liver dysfunction or other predisposing factors for DIC.
- Babies of mothers who were taking anticonvulsants, warfarin or antituberculous drugs at the time of delivery.
- All neonates undergoing surgery or tissue biopsy who have had previous bleeding problems.

**Thrombosis.** Congenital thrombophilia should be considered in:

- Any child with a clinically significant thrombosis, including spontaneous thrombotic events, unanticipated or extensive venous thrombosis, ischaemic skin lesions or purpura fulminans.
- A positive family history of neonatal purpura fulminans.

Asymptomatic neonates should **not** be investigated unless there is a significant medical history such as previous neonatal purpura fulminans or thrombosis. Parents need counselling before any investigations are performed either on themselves or their children so that the consequences of testing asymptomatic individuals can be fully explained.

## **2.LABORATORY INVESTIGATION OF NEONATAL HAEMOSTASIS, THROMBOSIS AND FIBRINOLYSIS.**

Laboratory investigation should identify neonates with inherited or acquired disorders of coagulation. The physiological deficiencies of procoagulant and anticoagulant proteins can make distinguishing the pathological from the physiological difficult and the correct interpretation of such investigations is dependant on an awareness of the 'normal' levels of these proteins in the neonate and how these are influenced by gestational age, postnatal age and by external factors such as sepsis or vitamin K deficiency. In particular, the diagnosis of mild congenital factor deficiencies will require repeat testing later in infancy for confirmation of the diagnosis. The gestation dependent differences between neonates and adults together with the evolving state of the newborn's coagulation system in the early weeks and months of life necessitate sequential reference ranges which reflect the effects of gestational and postnatal age. Since screening tests and factor assays are influenced by a number of variables including test methodology, reagents and instrumentation, laboratories should wherever possible establish their own normal ranges for neonates of different gestational ages (Hathaway and Corrigan 1991): practically, the difficulty of recruiting suitable cohorts of neonates can preclude this approach, with laboratory reference ranges then being based on literature derived data. The most frequently quoted data are those of Andrew et al who used a standardised protocol and venous blood samples from healthy term and preterm infants who had received 1mg of Vitamin K at least 12 hours prior to the first blood sample being drawn (see tables1-6).

## **INVESTIGATION OF THE NEONATE.**

### **A) SAMPLING.**

**1. Sample Collection.** Present day automated coagulometers have reduced the need for laboratories to establish manual microtechniques for coagulation screening. 1ml of blood is sufficient to perform a coagulation screen and an additional 1ml will be necessary for subsequent procoagulant or anticoagulant assays.

Blood sampling from a neonate should avoid contamination with intravenous fluids, particularly heparin, and should also avoid activation of the coagulation process. Neonatal units should have established their own blood discard procedures to minimise the risk of contamination; activation is likely if sampling is slow through plastic tubing and will result in a shortening of the PT, APTT and TT. Platelet clumping is common in such samples, resulting in spurious thrombocytopenia. All neonatal samples should be inspected for fibrin strands and platelet clumps to help interpretation of results.

**2. Sample Anticoagulant.** One ml sample tubes should be readily available to the Neonatal Unit. Ideally the volume of anticoagulant in the sample tube should be based on the volume of plasma and not on the total volume of blood taken. It should therefore be reduced in proportion to the increased neonatal haematocrit in order to avoid dilution of coagulation factors and this is particularly pertinent for neonates with very high haematocrits (Corrigan 1989). Laboratories and neonatal units usually take a more pragmatic approach to this problem and accept a degree of 'artefactual' prolongation of the coagulation times. Blood is therefore usually taken into 3.2% buffered sodium citrate, one part citrate to nine parts blood (NCCLS 1998, *Grade C recommendation based on level IV evidence*) and the normal values detailed in tables 1-6 have been obtained using this methodology.

Overfilled or underfilled samples should not be analysed.

**3. Sample Processing.** 24 hour access to laboratory support is essential, and this will include availability of factor assays.

## **B) LABORATORY INVESTIGATION:**

**1. HAEMOSTASIS.** Screening tests of neonatal haemostasis and their interpretation are described in Table 7. The investigation and management of neonatal thrombocytopenia are not within the remit of these guidelines but have recently been the subject of Practice Guidelines (Letsky et al 1996) and of extensive review (Roberts and Murray 1999).

Abnormal results require more specific testing of the various components of the haemostatic

system and should include :

- **Specific Factor assays.** Prolongation of the PT, APTT or TT which corrects in a 1:1 mix with normal plasma is indicative of either a single factor or multiple factor deficiencies. The gestational age, postnatal age, vitamin K status and 'general well being' of the neonate should all be considered in the interpretation of factor assays (see later).
- **Factor XIII Screen.** Factor XIII deficiency does not prolong any of the routine screening tests and requires specific investigation. Screening for this deficiency involves the use of calcium or thrombin to produce a fibrin clot and assessing the solubility of the clot in either 5M urea or 1% monochloroacetic acid. The results of such screening tests can be variable with thrombin based screens more sensitive to reductions in factor XIII (Jennings

et al 2000); factor XIII assays are not widely used in the UK but are more sensitive to lower levels of this protein ( UK NEQAS 1998).

- **Platelet Function.** The neonate's bleeding time is shorter than that of adults and of older children (Andrew et al 1990a), and may be influenced by a number of variables : testing must therefore be standardised [ *Grade B recommendations based on level IIa,b evidence,* ( Sutor 1998) ]. It is seldom indicated in the neonate and usually only performed when other more specific tests of haemostasis have failed to establish a cause of bleeding. Other “global” tests of platelet function using instruments such as the Platelet Function Analyser (PFA)<sup>100</sup> may provide an alternative to the bleeding time and are currently being evaluated in neonates. Formal platelet aggregation testing in the neonate requires significant amounts of platelet rich plasma (>150 µls). Variable results have been reported in otherwise healthy neonates, making interpretation of results difficult and in most cases, of little clinical significance.

Platelet glycoprotein expression is fully developed in term and premature neonates and flow cytometry can establish the diagnosis of the congenital disorders Bernard Soulier disease and Glanzmann's Thrombasthenia using minimal amounts of blood.

Investigation of the parents' platelet function may be helpful in selected cases.

- **D-Dimer.** D-dimer estimation is a specific test of fibrin lysis by plasmin and is a sensitive marker of coagulation activation, including disseminated intravascular coagulation. There are very few data on normal D-dimer levels in the neonate, but these have been reported to be increased in cord blood samples even in the absence of DIC because of the activation of coagulation which occurs during delivery (Hudson et al,1990).

**Table 7: Screening tests of neonatal haemostasis.**

Investigation	Result	Comment
1. Platelet count and morphology	< 150x10 <sup>9</sup> /l is abnormal, see text	Platelet clumping secondary to activation is common. Always look for fibrin strands in sample.
		Morphology important for congenital platelet disorders such as Bernard Soulier, grey platelet syndrome
2. Prothrombin Time (PT)	See text	Establish 'in-house' normal range* if possible. Prolonged by deficiencies of some Vitamin K dependent factors.
3. Activated Partial Thromboplastin Time (APTT)	See text	Establish 'in-house' normal range* if possible. Prolonged in healthy neonate because of relatively reduced levels of vitamin K dependent factors and contact factors.
4. Thrombin Clotting Time (TCT)	See text	Prolonged compared to adult TCT because of fetal fibrinogen. Addition of calcium to the buffering system shortens time to adult range and increases sensitivity.**
5. Fibrinogen.	See text	Equivalent to adult normal range but levels rise in the first week of life (NB when screening for DIC). Discrepancies between functional and immune assays helpful in diagnosis of dysfibrinogaemias.
6. Bleeding Time (BT)	See text	Infrequently performed. Shorter than adult range Modified template device for use in neonates.***

\*Results obtained are dependent on reagents and coagulometer used. It is therefore preferable to establish in-house normal ranges rather than rely on published data (see text).

\*\*Will be sensitive to hypofibrinogaemias, dysfibrinogaemias and the presence of heparin but not to the effects of fetal fibrinogen (Ockelford and Carter 1982).

\*\*\* Andrew et al 1990a

## **2. THROMBOSIS.**

The causative role of congenital deficiencies of anticoagulants in neonatal thrombosis is clear only in the homozygous/double heterozygous deficiencies of Protein C and Protein S which result in neonatal purpura fulminans : replacement of these proteins forms the basis of treatment for these conditions and the measurement of these proteins should be undertaken in all neonates who develop this condition. It is becoming increasingly recognised that there is a high prevalence of other thrombophilic defects in children who develop venous thrombosis (Junker et al 1999, Lawson et al, 1999, Heller et al, 2000), although the causative nature of these defects and their influence on the natural history of the thrombotic event remain uncertain : in order to justify the routine investigation of such defects, their demonstration should be shown to influence the treatment of an affected individual. At the present time this is not the case and so extensive thrombophilic screening of the neonate with thrombosis cannot be recommended as part of evidence based guidelines. It is not possible, however, to make the assumption that the aetiology of thrombosis in children and adults is similar or that the response to treatment and long term complications of thrombosis are the same in these two age groups. Clinicians should be aware that there are on-going International and National Registries for Paediatric Thrombosis which will in time accumulate data and thereby inform the investigation and treatment of childhood thrombosis: the provision of thrombophilic information is likely to form an important component of such registries.

The normal ranges of anticoagulant proteins in the neonate are wide and can make interpretation of results difficult. With the provisos mentioned above, laboratory investigations may include the following, test methodology having been addressed in BCSH guidelines for the investigation of thrombophilia ( Walker et al, 2001).

- ***Protein C Activity.*** Protein C is a Vitamin K dependent protein and levels are physiologically reduced in the newborn. Homozygous protein C deficiency is usually easily diagnosed in the neonate with levels often undetectable at presentation. In contrast, the wide range of protein C levels seen in the normal neonate can make heterozygous protein C deficiency difficult to diagnose and assays may have to be repeated after six months to confirm a deficiency. Assays of other vitamin K dependent coagulation proteins for comparison can be of help in the diagnosis, as can the measurement of parental levels of protein C .
- ***Protein S.*** Total protein S levels in the neonate are low when compared with adult ranges but the protein is present almost totally in its free form due to the low levels of C4 b binding protein (Schwarz et al 1988). Free protein S levels, however, are low when compared with adult values and increase to the adult range by 4 months of age, total protein S increasing similarly in the first 10 months of life. As with protein C, homozygous protein S deficiency is usually associated with low or undetectable levels of protein S in this age group and again, the heterozygous state can be difficult to diagnose definitively until a later age.
- ***Anti-thrombin.*** Functional AT levels are reduced in the term neonate and more so in the premature infant : they will remain reduced for at least the first 3 months of life.
- ***Resistance to activated Protein C.*** The wide variations in neonatal factor VIII levels make this an inappropriate test in this age group and the Factor V Leiden genotype should be looked for directly.

- ***Factor V Leiden.***
- ***Prothrombin<sup>20210A</sup>.***

Each of these single point mutations is associated with an increased risk of venous thrombosis in adults and children and is identified using PCR techniques (Bertina et al,1994, Poort et al,1996). Approximately 4% and 2% respectively of Caucasians are heterozygous for these gene defects. Their causative role in neonatal thrombosis is unknown but they may have a contributory role in the pathogenesis of thrombosis in this particular age group.

***Abnormalities of the Fibrinolytic System.*** : Plasminogen levels at birth are approximately 50% of adult values but homozygous plasminogen deficiency does not appear to be associated with thrombosis ( Mingers et al 1998) and it would therefore not seem justified to include this investigation in thrombophilia testing.

***Other investigations of thrombophilia.*** Babies of women with systemic lupus erythematosus and/or antiphospholipid syndromes may infrequently develop thrombosis in the presence of associated autoantibodies (lupus anticoagulant, anticardiolipin antibodies). Testing thrombotic neonates for these disorders in the absence of a maternal history is not justified because of the rarity of such findings.

Associations of neonatal thrombosis and other thrombophilic defects such as the methylenetetrahydrofolate reductase (MTHFR) T677T genotype and increased serum levels of lipoprotein a have recently been reported (Heller et al 2000).

### **3. THE MANAGEMENT OF SPECIFIC ACQUIRED DEFECTS OF HAEMOSTASIS.**

Vitamin K deficiency and disseminated intravascular coagulation (DIC) remain the major acquired haemostatic problems encountered in the neonate. The occurrence of intracranial and intraventricular haemorrhage in this age group has resulted in various prophylactic interventions being proposed but the lack of large controlled trials has made treatment recommendations difficult and a number of areas of controversy need to be resolved.

#### **[a] VITAMIN K DEFICIENCY**

Levels of the vitamin K dependent coagulation proteins (factor II, VII, IX, X) and the naturally occurring inhibitors protein C and protein S are physiologically low at birth and these proteins are functionally inactive in the absence of vitamin K.

Haemorrhagic disease of the newborn or, in current terminology, vitamin K deficiency bleeding (VKDB) can be classified as early, classical and late depending on the timing of presentation and the associated features (Sutor et al 1999).

**Diagnosis.** Isolated prolongation of the PT is the earliest laboratory evidence of vitamin K deficiency followed by prolongation of the APTT. The diagnosis is confirmed by correction of these parameters by vitamin K<sub>1</sub> or by assay of the specific factors and comparing with age adjusted normal ranges. Other confirmatory tests include measurement of decarboxyprothrombin (PIVKA II), the Echin Prothrombin time ratio and measurement of vitamin K concentrations but these assays are rarely available for routine laboratory use (Solano et al, 1990).

***The use of Vitamin K Prophylaxis.***

[a] In an attempt to reduce early VKDB, guidelines have been published on the management of pregnant women with epilepsy (Delgado-Escueta et al 1992). In addition to giving advice about the choice of anticonvulsant, intramuscular vitamin K (1mg) is recommended for all neonates together with antenatal administration of oral vitamin K (20mg/day) during the last 4 weeks of pregnancy. The latter recommendation is based on the finding of absent PIVKA II in the cord blood of women who received antenatal oral prophylaxis (Cornelissen et al, 1993, *Grade B recommendation based on level IIa evidence*).

[b] Vitamin K requirements in a neonate are estimated to be around 1 µg/kg/day. Classical VKDB can be prevented by the post-natal administration of a single dose of vitamin K (1mg) given orally or by intramuscular (IM) injection (Cornelissen et al 1997). One IM dose of vitamin K, with rare exceptions, will also prevent late VKDB but the same is not true following a single oral dose, particularly in high risk infants (McNinch and Tripp, 1991). Routine prophylaxis using parenteral vitamin K remains controversial following the report of an association between IM vitamin K and childhood cancer (Golding et al, 1992); a number of subsequent studies have failed to confirm this association and the current evidence has been reviewed recently (Zipursky, 1999).

**Despite the absence of clear supporting data, the controversy surrounding IM vitamin K and the risk of childhood cancer seems unlikely to be resolved in the short term. This has resulted in the continued use of parenteral vitamin K and to the development of alternative oral regimens, leading to a wide variation in prophylaxis policy both in the UK and worldwide.**

Currently it is recommended that all neonates receive post-natal vitamin K prophylaxis for the prevention of VKDB [*Grade B recommendation based on level III evidence*, McNinch and Tripp, 1991]. It is not possible at this time to make a firm recommendation on the optimal route or regimen to be used : however, in well babies vitamin K 1mg by IM injection or oral vitamin

K 1mg at birth with an additional 25µg per day thereafter for three months in infants who continue to be breast fed appear to be associated with the lowest risk of VKDB (*Grade B recommendation based on level III evidence*, Cornelissen et al 1997). Alternative oral regimes have also been shown to be effective, such as vitamin K 2 mg at birth followed by 1 mg weekly for three months in breast fed babies (*Grade B recommendation based on level III evidence*, Hansen and Ebbesen, 1996).

***Management of Vitamin K Deficiency Bleeding.*** Any infant suspected of VKDB should receive immediate intravenous vitamin K replacement : it is standard practice to administer a dose of 1mg which will usually result in correction within a few hours (*Grade C recommendation based on level IV evidence*) . Intravenous vitamin K can be associated with anaphylactoid reactions and should be administered by slow intravenous injection; if venous access cannot be established it can be given subcutaneously, the intramuscular route being avoided in the presence of a coagulopathy (*Grade C recommendations based on level IV evidence*, Sutor et al 1999 ).

In infants who are bleeding, FFP 10-15 ml/kg should be administered in addition to vitamin K(*Grade C recommendation based on level IV evidence*). This will raise the vitamin K clotting factors by 10-20 iu/dl : care should be taken to avoid increases in blood pressure secondary to rapid volume expansion. The use of Prothrombin Complex Concentrate (PCC) should be considered in the presence of life-threatening haemorrhage or intracranial haemorrhage where it is necessary to normalise the levels of the depleted coagulation factors. Whereas extrapolation of adult studies would suggest a dose of 50u/Kg it should be noted that there is no direct data available for the use of these concentrates in the neonate.

## **[b] DISSEMINATED INTRAVASCULAR COAGULATION (DIC)**



**Management of DIC:** The most important aspect of management is reversal of the underlying disease process. Acidosis should be corrected, tissue perfusion maintained and the neonate well oxygenated. Beyond this there are no clear guidelines on the optimal management of neonatal DIC and a virtual absence of recent randomised controlled trials addressing the available treatment options.

*All recommendations on the management of neonatal DIC are grade C based on level IV evidence.*

Blood product replacement is indicated for the treatment of clinical bleeding in the presence of laboratory confirmation of DIC. FFP (10-15 ml/kg) provides procoagulant proteins and the naturally occurring inhibitors, AT, Protein C and Protein S. Cryoprecipitate (10 ml/kg) contains a higher concentration of FVIII and fibrinogen per unit volume than FFP and is particularly useful in the presence of hypofibrinogenaemia. Platelet concentrates (10-15 ml/kg) may be necessary to maintain a platelet count of  $>50 \times 10^9/l$ . Paediatric platelet packs contain 60mls of concentrate and are therefore ideal for most neonatal transfusions : if such packs are not available an adult pack should be used. Volume reduction of adult packs may be clinically indicated but this process can result in platelet activation and aggregation, thereby reducing the in vivo efficacy of the platelets. Red cell concentrates may be required and exchange transfusion may be necessary to avoid volume overload.

Thrombosis can be as problematic as bleeding in DIC and heparin should be given in obvious thrombotic DIC. The administration of naturally occurring coagulation inhibitors such as AT and PC has been shown to be of benefit in specific cases of adult DIC associated with multi organ failure (Eisele et al 1998, Smith et al 1997) although it is not known if this is applicable to similarly affected neonates : in the absence of clinical trials heparin, AT or PC either alone or in combination cannot currently be recommended for the routine treatment of neonatal DIC.

#### **[c] INTRAVENTRICULAR / INTRACRANIAL HAEMORRHAGE**

Periventricular-intraventricular haemorrhage is the most common form of ICH in preterm infants of low birth weight with an incidence of around 15-20% for infants less than 32 weeks gestation. (Oh et al, 1996). The aetiology is multifactorial with alterations in cerebral blood flow, fragility of the immature germinal matrix vessels and endothelial ischaemia being more significant than impaired haemostasis.

Various therapeutic modalities have been employed in an attempt to reduce the incidence of IVH, including measures to improve haemostasis. There has been no consistent benefit achieved by the prophylactic use of FFP or platelets in high risk infants (Wright et al, 1995; Anon,1996, Andrew et al 1993) and these blood products should not therefore be routinely administered to such children. It is, however, common practice to transfuse platelets prophylactically when the platelet count falls below  $30 \times 10^9/l$  in an otherwise well infant or below  $50 \times 10^9/l$  in the sick preterm neonate.

Information is also limited on the optimal management of a neonates with a pre-existing IVH : it would however, seem appropriate to correct a coagulation abnormality and maintain a platelet count of  $>50 \times 10^9/l$  in order to prevent extension of the bleed (*Grade C recommendation based on level IV evidence*). An inherited coagulation disorder should always be excluded in any neonate with an apparently spontaneous ICH (*Grade C recommendation based on level IV evidence*).

#### **{D} THE MANAGEMENT OF INHERITED COAGULATION DEFICIENCIES.**

The vast majority of bleeding problems seen during the neonatal period are due to acquired haemostatic disorders. However, inherited coagulation disorders can present in the neonatal period and there may be no preceding family history to suggest the diagnosis.

***Perinatal management.*** In the presence of a positive family history of an inherited coagulation deficiency, pregnancy and delivery should be managed in such a way as to reduce the potential risk of bleeding in both the mother and baby to a minimum. This should entail the close liaison

of the Obstetric and Neonatal Units and the local Haemophilia Centre so that a management plan exists for the delivery and for the subsequent investigation and treatment of the neonate. The management of such women has been the subject of recent guidelines (Haemostasis and Thrombosis Task Force, 1994) .

Rarely, factor replacement therapy may be required urgently following delivery and access to appropriate treatment should be arranged prior to delivery. At birth a cord blood sample should be obtained for the relevant coagulation factor investigations.

Historically the risk of intracranial haemorrhage in neonatal haemophilia A or B has appeared to be low. However, a recent literature review has described a cumulative incidence for intracranial and extracranial haemorrhage of 3.58% (Kulkarni and Lusher 1999). Prophylactic administration of factor VIII concentrate to the neonate may reduce this incidence or modify the bleed (Buchanan 1999) although no evidence currently exists to support this as routine practice. Whereas cranial ultra-sound findings from large prospective series are lacking, scanning of the head should at the least be undertaken in the first hours after delivery if there has been any trauma during delivery and in other congenital deficiency states where the risk of ICH is higher e.g. FXIII, FVII, FX, deficiency [*Grade C recommendation based on level IV evidence* (Girolami et al 1985, Anwar and Miloszewski 1999)].

***Clinical Features.*** In the absence of a positive family history, the diagnosis may be suspected by the presence of abnormal bleeding, which usually occurs in the context of an otherwise healthy infant. The haemophilias are the commonest inherited bleeding disorders to present in the neonatal period. The pattern of bleeding observed in neonates is often iatrogenic in origin and can be characterised by continued oozing or excessive haematoma formation following venepuncture, heel stab sampling or the administration of intramuscular vitamin K. Significant haemorrhage can occur following circumcision. Umbilical bleeding is relatively uncommon in haemophilia and is typically associated with severe hypofibrinogenaemia and homozygous

factor XIII deficiency. Likewise, ICH occurs infrequently in haemophiliacs but is a significant cause of morbidity and mortality in the severe forms of factor VII, factor X and factor XIII deficiency (Girolami et al 1985).

**Diagnosis.** Factor VIII levels are within the normal adult range in both term and preterm infants and it is therefore possible to confirm a diagnosis of haemophilia A in the neonatal period regardless of gestational age and severity. This also applies to deficiencies of fibrinogen and factor V. The diagnosis of severe (<2 iu/dl) and moderate (2-5 iu/dl) haemophilia B can also be confirmed in the neonatal period. However, confirmation of mildly (>5 iu/dl) affected cases is problematic due to overlap with the normal range necessitating repeat testing at around 6 months of age.

von Willebrand disease is caused by quantitative or qualitative defects of von Willebrand factor (Sadler, 1994). This factor is an acute phase protein and physiological increases make the diagnosis of Type 1 vWD difficult in the neonate. Type 2 vWD can be suspected from discrepancies in the plasma levels of VWF antigen and activity and some subtypes may be confirmed by analysis of vWF multimers, although the relative lack of vWF-cleaving protease in the neonate can make such analysis difficult. Type 3 von Willebrand disease can be diagnosed in neonates who have essentially a total deficiency of von Willebrand factor. Knowledge of the particular molecular defect occurring in the family will also be of value where the diagnosis is in doubt.

Homozygous deficiencies of factors II, VII, X and XI can be diagnosed in the neonatal period, whereas levels in heterozygotes may overlap with the normal range precluding confident identification at this stage. Exclusion of Factor XIII deficiency should be carried out in neonates having characteristic bleeding patterns accompanied by normal coagulation screening tests.

**Management.** Where there is clinically significant ongoing haemorrhage and a congenital factor deficiency is suspected but not confirmed, fresh frozen plasma (10-15ml/kg) may be administered while the results of laboratory investigations are awaited (*Grade C recommendation based on level IV evidence*). Guidelines for the treatment of hereditary coagulation disorders have recently been published by the UK Haemophilia Centres Doctors' Organisation (UKHCDO, 1997) and management of these disorders should always be undertaken in conjunction with the local Haemophilia Centre or Comprehensive Care Centre. Recombinant factor VIII and recombinant factor IX concentrates carry the lowest risk of transmitting viral infection and are the treatment of choice for neonates with haemophilia A and B [*Grade B recommendation based on level III evidence, (UKHCDO 1997)*]. If recombinant products are not available, a high purity, viricidally inactivated plasma derived concentrate should be used [*Grade B recommendation based on level III evidence, (UKHCDO 1997)*]. There is little information available on the pharmacokinetics of replacement therapy in neonates and dosing is therefore based on schedules used in older children and adults (Rickard, 1995). Due to the risks of hyponatraemia and water intoxication, DDAVP should **not** be used in the treatment of neonatal vWD . A viricidally treated intermediate purity factor VIII concentrate containing the high molecular weight multimers of von Willebrand factor remains the treatment of choice [*Grade C recommendation based on level IV evidence (UKHCDO 1997)*]. The treatment of bleeding secondary to other inherited deficiency disorders should be with specific high purity factor concentrates where these products exist (fibrinogen, factor VII, factor XI, factor XIII) or alternatively with prothrombin complex concentrate (PCC) for deficiencies of factor II or factor X and fresh frozen plasma for factor V deficiency. (*Grade C recommendation based on level IV evidence*). Although specific concentrates are usually plasma derived, recombinant factor VIIa may provide an alternative to plasma derived factor VII for the treatment of inherited factor VII deficiency (Billio et al 1997). Factor XI concentrate and PCCs should be used with care in the neonatal period because of the potential risk of thrombosis: there

are few data available on the use of these products in neonates and FFP may provide a safer alternative. Neonates found to have homozygous factor XIII deficiency are at significant risk of ICH and are likely to benefit from routine prophylaxis maintaining plasma factor XIII levels of above 3 iu/dl. Current regimens utilise a dose of 30 iu/kg administered once monthly. If factor XIII concentrate is not available FFP 5-10 mls/kg can be used.

Prophylaxis during the neonatal period should also be considered in severe homozygous FVII and FX deficiency although even with appropriate replacement therapy significant haemorrhage may still occur (*Grade C recommendation based on level IV evidence*).

All infants who may require treatment with factor concentrates should be vaccinated against hepatitis B (*Grade C recommendation based on level IV evidence*). This should be administered subcutaneously with pressure applied over the injection site for 5 minutes. Hepatitis A vaccination should not be administered until the child is at least one year old.

#### **{e} NEONATAL THROMBOSIS.**

Neonates and infants less than one year of age account for the largest proportion of thrombotic events seen in the paediatric population (Andrew et al 1994a). These events, however, remain relatively uncommon and often occur in sick term and preterm infants : the most important risk factor for the development of thrombosis during the neonatal period is the presence of an indwelling central line and consequently the vessels involved tend to be those most frequently used for catheterisation. Other documented risk factors for the development of neonatal thrombosis include asphyxia, septicaemia, dehydration, maternal diabetes and cardiac disease.

Spontaneous, non-catheter related thrombotic events are uncommon in the neonatal period and most frequently involve the renal vein. The majority of cases of renal vein thrombosis present during the first few days of life and in approximately a quarter of these the thrombosis is bilateral with a smaller proportion also developing extension into the inferior vena cava.

***Predisposing factors.*** Acquired deficiencies of protein C and protein S, particularly in sick, preterm infants, may increase the risk of thrombosis (Manco-Johnson et al 1991). At present, the impact of inherited prothrombotic defects on both catheter related and spontaneous thrombotic events in the neonatal period remains poorly defined though it seems likely that these will become increasingly recognised as contributory factors in this setting (Heller 2000). Neonatal thrombotic events have occasionally been reported in association with maternal systemic lupus erythematosus due to the transplacental passage of antiphospholipid antibodies (Tabbutt et al 1994).

***Diagnosis of Neonatal Thrombosis.*** Thrombosis must be confirmed objectively before undertaking thrombolytic treatment or anticoagulation given the significant risks of such treatment in this age group.

Doppler ultrasound methods are the most frequently used scanning techniques and provide readily available, non-invasive imaging giving valuable diagnostic information. Reliance on Doppler can fail to diagnose thrombosis in particular sites such as the aorta, right atrium and inferior vena cava in neonates with umbilical artery or venous catheters when compared with the use of contrast angiography (Roy et al 1997, Vailas et al 1986). Similar problems are likely to exist with imaging of the upper limb venous system and the most recent recommendation of the Scientific and Standardisation Subcommittee on Neonatal Haemostasis is that contrast angiography remains the “gold standard” imaging technique for the confirmation of thrombotic vessel occlusion, particularly where thrombolytic therapy or surgery is planned [*Grade B recommendation based on level III evidence* (Schmidt & Andrew 1992)]. Linograms, where dye is injected via a central venous line, are not a substitute for venography and may fail to demonstrate extensive thrombosis.

CT and MRI scanning are indicated for imaging of thrombosis-related problems of the CNS.

**Management of Neonatal Thrombosis.** The management of arterial and venous thromboembolic events in the neonatal period remains controversial and it is generally acknowledged that there is an urgent need for large multicentre studies on which to base recommendations . Treatment options include supportive care only, anticoagulant therapy with heparin or low molecular weight heparin (LMWH), thrombolytic therapy and surgery. Warfarin is not indicated in the neonatal period because of the difficulties in establishing consistent levels of anticoagulation.

*All Recommendations on the management of neonatal thrombosis are Grade C, based on level IV evidence, unless otherwise stated.*

**Supportive Therapy.** In the absence of controlled studies indicating the efficacy of more aggressive therapy, supportive care alone may be appropriate management for clinically silent thrombosis, which will therefore include the majority of small, asymptomatic catheter related events (Schmidt & Andrew1992). Regular objective monitoring should be performed to detect extension of the original thrombus and in the case of catheter related events, catheter removal is recommended.

**Anticoagulant Therapy.** In the presence of more extensive, clinically significant thrombosis, particularly where there is evidence of organ or limb dysfunction, consideration should be given to the use of anticoagulant therapy. Unfractionated heparin remains the most frequently used anticoagulant, although there is increasing experience with LMWH in this age group.

The use of heparin in the neonatal period is complicated by the physiological immaturity of the haemostatic system, with reduced levels of antithrombin resulting in relative heparin resistance (Schmidt et al,1988).

A dosage regimen for unfractionated heparin has been suggested by Andrew et al (1994b) and is shown in table 9. [*Grade B recommendation based on level IIb evidence*, (Andrew et al, 1994b)].

**Table 9. Heparinisation of neonates and dose adjustment.**

- Loading dose of heparin : 75iu/kg , then
- Continuous infusion : 28iu/kg/hour
- Monitor using an APTT or heparin assay, taking first blood sample 4 hours after loading dose. Use nomogram for dose adjustment.

In the absence of a validated therapeutic range for the use of heparin in neonates, the APTT should be prolonged to a therapeutic range corresponding to an anti-Xa level of 0.35-0.7 units/ml, although the limitations of the anti-Xa level should be noted ( it provides a guide to the pharmacokinetics of heparin and only limited information on the anticoagulant and prohaemorrhagic effects in vivo of this drug. Also, standard anti Xa assays will tend to underestimate heparin unless the neonatal antithrombin deficiency is fully corrected in the test system).

Nomograms are available for dose adjustment (Andrew et al, 1994b), and can be modified by individual laboratories in order to achieve their own therapeutic APTT range

Thrombocytopenia is common in the sick neonate and every attempt should be made to maintain a platelet count above  $50 \times 10^9/l$  during heparin therapy.

The optimal duration of anticoagulation remains undefined but short term therapy (e.g. 10-14 days) is commonly used, with objective radiological monitoring performed both during and

after completion of anticoagulant therapy. If there is evidence of new or extending thrombus following completion of initial therapy, heparin should be recommenced.

**Low molecular weight heparin** is becoming increasingly used in the treatment of neonatal thrombosis. Dose finding studies have been published and indicate that as with standard heparin dose requirements in the neonate are higher than in older children (Massicotte et al 1996, Nohe et al 1999) For example, the recommended dose of enoxaparin is 1.5 mg/kg/dose administered subcutaneously twice per day which should result in a therapeutic anti-Xa level of between 0.5-1.0 units/ml by chromogenic assay at 4 hours post dose [*Grade B recommendation based on level IIB evidence*, (Massicotte et al 1996) ].

***Thrombolytic Therapy.*** Thrombolytic therapy should be considered in the presence of extensive thrombosis with organ dysfunction or where limb viability is threatened. Such therapy should not be used within 10 days of surgery or in the presence of pre-existing bleeding problems.

Streptokinase, urokinase and tissue plasminogen activator (t-PA) have all been used in neonates but overall experience is relatively limited and results conflicting (Chalmers and Gibson ,1999). As with heparin the response to thrombolytic agents in the neonate is significantly different from that seen in older children, reflecting physiologically reduced levels of plasminogen. *In vitro* studies have demonstrated that t-PA is more effective than streptokinase and similar to urokinase at lysing thrombi in plasmas with decreased concentrations of plasminogen. t-PA and urokinase are therefore the preferred agents for thrombolytic therapy in neonates. Recommended dosing regimens are shown in table 10 [*Grade B recommendation based on evidence level IIB* (Leaker et al 1996)].

**Table 10 : Thrombolytic regimes in the neonate.**

<u>Drug</u>	<u>Bolus</u>	<u>Maintenance</u>	<u>Duration</u>
Urokinase	4400 u/kg	4400 u/kg/hr	6 -12 hours
t-PA	None	0.1-0.6 mg/kg/hr	6 hours

There is no laboratory therapeutic range for thrombolytic agents and successful lysis is confirmed on clinical and radiological changes : monitoring should therefore be performed during thrombolytic therapy to assess the response to treatment and the duration of therapy will vary depending on this response. Failure to induce lysis of the thrombus may indicate the need for plasminogen supplementation with FFP.

In order to reduce the risk of bleeding in the neonate receiving fibrinolytics, it is recommended that fibrinogen is maintained at >1 g/l using cryoprecipitate and the platelet count at > 50 x 10<sup>9</sup>/l by transfusion (*Grade C, level IV evidence*).

The use of heparin either during or after completion of thrombolytic therapy is controversial: if given, a dose of 28iu/Kg/hr is appropriate in the neonate.

***Prophylactic anticoagulation.*** Heparin prophylaxis is recommended for neonates with indwelling umbilical artery catheters and those undergoing cardiac catheterisation. Umbilical artery patency can be prolonged by the use of low dose heparin (3-5 u/hr) by continuous infusion [*Grade B recommendation based on level IIb evidence* (Sutor et al 1997)]. Whether the incidence of clinically significant thrombi is also reduced is not clear. Thrombotic complications associated with cardiac catheterisation can be reduced by the administration of a bolus of heparin (100-150 units/kg) as the femoral artery is catheterised (Freed et al,1974). A second bolus may be required for prolonged procedures.

## **{6} CONGENITAL HOMOZYGOUS PROTHROMBOTIC DISORDERS.**

### **(a) Protein C and Protein S deficiencies.**

Homozygous (or compound heterozygous) deficiencies of protein C and protein S (plasma activities < 0.01 U/ml) are rare conditions and usually present as life threatening disorders in the neonatal period (Marlar & Neumann,1990). A less severe form of protein C deficiency where the level of protein C, although reduced, remains detectable (0.02-0.23 U/ml), may present in the neonatal period, although does so more commonly in later life (Sharon et al,1986).

***Clinical Features.*** Onset is usually within the first few days of life and can occur within hours of birth. The microcirculation is characteristically affected first with the development of purpura fulminans associated with laboratory evidence of DIC. Cerebral and renal vein thrombosis are common and can be presenting features. Ocular manifestations are also characteristic and it is likely that cerebral and ophthalmic thrombosis often occur as intrauterine events. Although purpura fulminans is almost always a feature, major vessel thrombosis occasionally occurs in isolation.

***Diagnosis.*** In the acute untreated phase baseline laboratory results are frequently indicative of DIC. The definitive diagnosis can be difficult in the neonate. Protein C and protein S levels are physiologically reduced at birth and are further reduced in the presence of DIC, during which protein C in particular can reach very low levels. The diagnosis is therefore based on finding undetectable protein C (or protein S) activity (< 0.01 U/ml) with heterozygous levels in the parents. Where the molecular defect is known prenatal diagnosis can be offered to families when there is a prior history of neonatal purpura fulminans.

**Management.** The most important aspect of management in the acute phase is the immediate and adequate replacement of the deficient inhibitor. Protein C deficient neonates should receive Protein C concentrate at a starting dose of 40 IU/kg, subsequent dosage being based on protein C recovery data. If concentrate is not immediately available, FFP 10-20mls/kg should be used as a temporary measure. During the early stages of replacement therapy when DIC is ongoing the half life of the infused protein C may be as short as 2 - 3 hours, necessitating frequent dosing. This usually improves to about 10 hours once the DIC is controlled, enabling a single daily treatment to be given (Dreyfus et al,1995). Protein C levels should remain in excess of 0.25U/ml to prevent further thrombosis (Muller et al,1996). Replacement therapy is required for an initial period of at least 6-8 weeks to facilitate resolution of clinical lesions.

There is no currently available protein S concentrate and FFP is therefore used for replacement therapy (10-20 ml/kg every 8 to 12 hours) [*Grade C recommendation based on level IV evidence*].

Long term management remains controversial but current regimens utilise oral anticoagulants with or without concomitant replacement therapy. It is difficult to warfarinise infants until their vitamin K dependent factors have physiologically increased and affected babies should preferably receive replacement therapy. Older children receiving warfarin seem to require an INR at the upper end of the therapeutic range (3.0-4.5) to prevent recurrent skin necrosis (*Grade C recommendation based on level IV evidence*) and therefore require careful monitoring. Where possible, dosing should be individualised to identify the minimum dose required to remain symptom free. In the event of recurrent problems during warfarin therapy, temporary or longer term reintroduction of protein C replacement may be required.

Similar problems have been reported in the management of homozygous protein S deficiency where again intermittent replacement with FFP may be required in addition to oral anticoagulants (Mahasandana et al, 1996)

Low molecular weight heparin may be a useful therapeutic option in the long term treatment of homozygous protein C deficiency in which plasma levels remain detectable but its place in the management of cases with undetectable levels has not been determined (Monagle et al 1998).

#### **Other Homozygous Defects.**

Homozygous AT deficiency has been recorded very infrequently. Type I defects are probably incompatible with life and the majority of reports relate to Type II HBS defects (Chowdury et al 1994). Long term anticoagulation has been successfully used in this disorder.

Homozygosity for the Factor V Leiden mutation rarely presents in childhood and a significant number of adults with this mutation also remain symptom free throughout their lives, the same being true for individuals homozygous for the PT<sup>20210A</sup> mutation.

#### **ACKNOWLEDGEMENTS**

The authors and the Haemostasis and Thrombosis Task Force wish to acknowledge the helpful, constructive comments made on this document by British Society of Haematology members and by other representatives of professional bodies including the Royal College of Paediatrics and Child Health, the British Association for Paediatric Medicine and the Paediatric Haematology Forum.

#### **RECOMMENDED REVIEW AND EXPIRY DATE of this GUIDELINE.**

- 1. Review date : 5 years from publication**
- 2. Expiry date : 6 months after review date.**

## References

Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, Bernstein M, Brisson L, Cairney B, DeSai D, Grant R, Israels S, Jardine L, Luke B, Massicotte P, Silva M. (1994a). Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. *Blood*, **83**, 1251-1257.

Andrew M, Marzinotto V, Massicotte P, Blanchette V, Ginsberg J, Brill-Edwards P, Burrows P, Benson L, Williams W, David M, Poon A, Sparling K. (1994b). Heparin therapy in pediatric patients: a prospective cohort study. *Pediatric Research* , **35**, 78-83 .

Andrew M, Paes B, Bowker J, Vegh P. (1990a). Evaluation of an automated bleeding time device in the newborn. *American Journal of Hematology*, **35**, 275-277.

Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle, Powers P. (1988). Development of the human coagulation system in the healthy premature infant. *Blood* **80**, 1998-2005.

Andrew M, Paes B, Milner R, Johnson M, Mitchell L, Tollefsen DM, Powers P. (1987). Development of the coagulation system in the full-term infant. *Blood*, **70**, 165-172.

Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. (1990b). *American Journal of Pediatric Hematology/ Oncology*, **12**, 95-104.

Andrew M, Vegh P, Caco C, Kirplani H, Jefferies A, Ohlsson A, Watts J, Saigal S, Milner R, Wang E. (1993). A randomised controlled trial of platelet transfusions in thrombocytopenic premature infants. *Journal of Paediatrics*, **123**: 285-291.

Anonymous.(1996). A randomised trial comparing the effect of prophylactic intravenous fresh frozen plasma, gelatin or glucose on early mortality and morbidity in preterm babies. The Northern Neonatal Nursing Initiative [NNNI] Trial Group. *European Journal of Pediatrics*, **155**, 580-588.

Anwar R and Miloszewski KJA. (1999). Factor XIII deficiency. *British Journal of Haematology*, **107**, 468-484.

Bertina RM, Koelman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. (1994). Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature*, **369**, 64-7.

Bick RL. (1995). Disseminated intravascular coagulation: objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. *Clin Appl Thrombosis/Haemostasis*, 3-23.

Billio A, Pstcosta N, Rosanelli C, Amaddii G . (1997). Successful short term oral surgery prophylaxis with rFVIIa in severe congenital factor VII deficiency. *Blood Coagulation and Fibrinolysis*, **8**, 249-250.

Buchanan GB. (1999). Factor concentrate prophylaxis for neonates with haemophilia. *Journal of Paediatric Haematology/ Oncology*, **21**, 254-256.

Chalmers EA, Gibson BES. (1999). Thrombolytic therapy in the management of paediatric thromboembolic disease. *British Journal of Haematology*, **104**, 14-21.

Chowdury V, Lane DA, Mille B, Auberger K, Gandenberger-Bachem S, Pabinger I, Olds RJ, Thein SL. (1994). Homozygous antithrombin deficiency : Report of two new cases (99Leu to Phe) associated with venous and arterial thrombosis. *Thrombosis and Haemostasis*, **72**, 198-202.

Cornelissen M, Steegers-Theunissen R, Kollee L, Eskes T, Vogels-Mentik G, Motohara K, De Abreu R, Monnens L. (1993). Increased incidence of neonatal vitamin K deficiency resulting from maternal anti convulsant therapy. *American Journal of Obstetrics and Gynaecology*, **168**, 923-928.

Cornelissen M, von Kries R, Loughnan P, Schubiger G. (1997). Prevention of vitamin K deficiency bleeding: efficacy of different multiple oral dose schedules of vitamin K. *European Journal of Paediatrics*, **156**, 126-130.

Corrigan JJ.(1989). Neonatal Coagulation Disorders. *Perinatal Haematology* **21**, 167

Delgado-Escueta AV, Janz D. (1992) Consensus guidelines: preconception counselling, management, and care of the pregnant woman with epilepsy. *Neurology*, **42** (Suppl. 5): 149-160.

Dreyfus M, Masterton M, David M, Rivard GE, Muller F-M, Kreuz W, Beeg T, Minford A, Allgrove J, Cohen JD, Christoph J, Bergmann F, Mitchell VE, Haworth C, Nelson K, Schwarz HP. (1995). Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. *Seminars in Thrombosis and Haemostasis*, **21**, 371-381.

Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, Fourrier F, Heinrichs H, Delvos U. (1998). Antithrombin III in patients with severe sepsis. A randomised, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomised, placebo-controlled, double-blind trials with anti-thrombin III in severe sepsis. *Intensive Care Medicine*, **24**, 663-672.

Freed MD, Keane JF, Rosenthal A. (1974). The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. *Circulation*, **50**, 565-569.

Girolami A, De Marco L, Dal Bo Zanon R, Patrassi R, Cappellato MG. (1985). Rarer quantitative and qualitative abnormalities of coagulation. *Clinics in Haematology*, **14**, 385-411.

Golding J, Birmingham K, Greenwood R, Mott M. (1992). Intramuscular Vitamin K and childhood cancer. *British Medical Journal* , **305**, 341-346.

Haemostasis and Thrombosis Task Force. (1994). Investigation and management of haemorrhagic disorders in pregnancy. *Journal of Clinical Pathology*, **47**, 100-108.

Hansen KN and Ebbesen F. (1996). Neonatal vitamin K prophylaxis in Denmark : three years' experience with oral administration during the first three months of life compared with one oral administration at birth. *Acta Paediatrica* , **85**, 1137-1139.

Hathaway W, Corrigan J. (1991). Report of Scientific and Standardisation Subcommittee on Neonatal Haemostasis. Normal coagulation data for fetuses and newborn infants. *Thrombosis and Haemostasis*, **65**, 323-325.

Heller C, Schobess R, Kurnik K, Junker R, Günther G, Kreuz W, Nowak-Göttl U. (2000).

Abdominal venous thrombosis in neonates and infants : role of prothrombotic risk factors – a multicentre case-control study. *British Journal of Haematology*, **111**, 534-539.

Hudson IRB, Gibson BES, Brownlie J, Holland BM, Turner TL, Webber RW. (1990) Increased concentrations of D-Dimers in newborn infants. *Archives of Disease in Childhood*, **65**, 383-389.

Jennings I, Woods TAL, Kitchen S, Preston FE. (2000). Detection of factor XIII deficiency : which test? *British Journal of Haematology*, **108**, suppl1 : 146a

Junker R, Koch H-G, Auberger K, Münchow N, Ehrenforth S, Nowak-Göttl. (1999). Prothrombin G20210A Gene Mutation and further prothrombotic risk factors in childhood thrombophilia. *Arteriosclerosis and Thrombosis Vascular Biology*, **19**, 2568-2572.

Kulkarni R and Lusher JM. (1999). Intracranial and extracranial haemorrhages in newborns with haemophilia: a review of the literature. *Journal of Paediatric Haematology/Oncology*, **21**, 289-295.

Lawson SE, Butler D, Enayat MS, Williams MD. (1999). Congenital thrombophilia and thrombosis : a study in a single centre. *Archives of Disease in Childhood*, **81**, 176-178.

Leaker M, Massicotte P, Brooker LA, Andrew M. (1996). Thrombolytic therapy in pediatric patients: A comprehensive review of the literature. *Thrombosis and Haemostasis*, **76**, 132-134.

Letsky E, Greaves M on behalf of the Maternal and Neonatal Haemostasis Working Party of the Haemostasis and Thrombosis Task Force of the British Society for Haematology. (1996). Guidelines on the investigation and management of thrombocytopenia in pregnancy and neonatal alloimmune thrombocytopenia. *British Journal of Haematology*, **95**, 21-26.

M<sup>c</sup>Ninch AW, Tripp JH. (1991). Haemorrhagic disease of the newborn in the British Isles : two year prospective study. *British Medical Journal*, **303**, 1105-1109.

Mahasandana C, Veerakul G, Tanphaichitr VS, Opartkiattikul N, Hathaway WE. (1996). Homozygous protein S deficiency: 7 year follow-up. *Thrombosis and Haemostasis*, **76**, 1122

Mammen EF (1983). Fibrinogen abnormalities. *Seminars in Thrombosis and Haemostasis*, **9**, 1-9

Manco-Johnson MJ, Abshire TC, Jacobson LJ, Marlar RA. (1991). Severe neonatal protein C deficiency: Prevalence and thrombotic risk. *Journal of Pediatrics*, **119**, 793-798.

Marlar RA, Neumann A. (1990). Neonatal purpura fulminans due to homozygous protein C or Protein S deficiencies. *Seminars in Thrombosis and Haemostasis*, **16**, 299-310.

Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. (1996). Low molecular weight heparin in pediatric patients with thrombotic disease: a dose finding study. *Journal of Pediatrics*, **128**, 313-318 .

Mingers AM, Philapitsch A, Schwarz HP, Zeitler P, Kreth HW. (1998). Polymorphonuclear elastase in patients with homozygous type I plasminogen deficiency and ligneous conjunctivitis. *Seminars in Thrombosis and Hemostasis*, **24**, 605-612.

Monagle P, Andrew M, Halton J, Marlar R, Jardine L, Vegh P, Johnston M, Webber C, Massicotte P (1998). Homozygous protein C deficiency: description of a new mutation and successful treatment with low molecular heparin. *Thrombosis and Haemostasis*, **79**, 756-761

Muller FM, Ehrental W, Hafner G, Schranz D. (1996). Purpura fulminans in severe congenital protein C deficiency: monitoring of treatment with protein C concentrate. *European Journal of Pediatrics*, **155**, 20-25.

NCCLS. (1998). Collection, transport and processing of blood specimens for coagulation testing and general performance of coagulation assays; *Third Edition. NCCLS document H21-A3*, **18**, 3.

Nohe N, Flemmer A, Rümmler R, Praun M, Auberger K. (1999). The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood : a report on 48 cases. *European Journal of Pediatrics*, **158**, S134-S139.

Ockelford PA, Carter CJ. (1982). Disseminated intravascular coagulation: the application and utility of diagnostic tests. *Seminars in Thrombosis and Haemostasis*, **8**, 198-216

Oh W, Fanaroff AA, Verter J, Stevenson DK, Papile L-A, Stoll BJ, Lemons JA, Bauer CR, Wright LL. (1996). Neonatal mortality and morbidity in very low birth weight infants: a seven year trend analysis of the Neonatal Network Data. *Paediatric Research*, **39**, 235A.

Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. (1996). A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood*, **88**, 3698-3703.

Rickard KA. (1995). Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. *Haemophilia*, **1**, (Suppl. 1): 8-13

Roberts IAG, Murray NA. (1999). Management of thrombocytopenia in neonates. *British Journal of Haematology*, **105**, 864-870.

Roy M, Turner-Gomes S, Gill G, Mernagh J, Gillie P, Schmidt B. (1997). Incidence and diagnosis of neonatal thrombosis associated with umbilical venous catheters. *Thrombosis and Haemostasis*, **78**, PS2953.

Sadler JE. (1994). A revised classification of von Willebrand disease. *Thrombosis and Haemostasis*, **71**, 520-525.

Schmidt B, Andrew M (for the subcommittee). (1992). Report of the Scientific and Standardization Subcommittee on Neonatal Hemostasis: Diagnosis and treatment of neonatal thrombosis. *Thrombosis and Haemostasis*, **67**, 381-382

Schmidt B, Buchanan M, Ofofu F, Brooker L, Hirsh J, Andrew M. (1988). Antithrombotic properties of heparin in a neonatal piglet model of thrombin induced thrombosis. *Thrombosis and Haemostasis*, **60**, 289-292.

Schwarz HP, Muntean W, Watzke H, Richter B, Griffin JH (1988). Low total protein S antigen but high protein S activity due to decreased C4b-binding protein in neonates. *Blood*, **71**, 562-565.

Sharon C, Tirindelli MC, Mannucci PM, Tripodi A, Mariani G. (1986). Homozygous protein C deficiency with moderately severe clinical symptoms. *Thrombosis Research*, **41**, 483-488.

Smith OP, White B, Vaughan D, (1997). Use of protein C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. *Lancet*, **35**,: 1590-1593.

Solano C, Cobcroft RG, Scott DC. (1990). Prediction of vitamin K response using the Echis time and the Echis-prothrombin time ratio. *Thrombosis and Haemostasis*, **64**, 353-357.

Sutor AH. The bleeding time in paediatrics. (1998). *Seminars in Thrombosis and Haemostasis*, **24**, 531-543.

Sutor AH, Massicotte P, Leaker M, Andrew M. (1997). Heparin therapy in paediatric patients. *Seminars in Thrombosis and Haemostasis*, **23**, 303-319

Sutor AH, von Kries R, Cornelissen E.A.M, McNinch AW, Andrew M, on behalf of the ISTH Paediatric/Perinatal Subcommittee. (1999). Vitamin K Deficiency Bleeding (VKDB) in Infancy. *Thrombosis and Haemostasis*, **81**, 456- 461.

Tabbutt S, Griswold WR, Ogino MT, Mendoza AE, Allen-JB, Reznik VM. (1994). Multiple thromboses in a premature infant associated with maternal phospholipid antibody syndrome. *Journal of Perinatology*, **14**,(1): 66-70

UK NEQAS for blood coagulation. (1998). Survey 112: Factor XIII Exercise.

United Kingdom Haemophilia Centre Directors Organisation Executive Committee. (1997). Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. *Haemophilia*, **3**, 63-77

US Department of Health and Human Services, Public Health Service and Agency Care Policy and Research. (1992). Acute Pain Management: Operative or Medical Procedures and Trauma. *Report AHCPH Pub. 92-0038, Agency for Health Care Policy and Research Publications.*

Vailas GN, Brouillette RT, Scott JP, Shkolnik A, Conway J, Wiringa K. (1986). Neonatal aortic thrombosis: recent experience. *Journal of Pediatrics*, **10**, 101-108.

Walker ID, Greaves M, Preston FE. on behalf of the Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology (2001). Investigation and management of heritable thrombophilia. *British Journal of Haematology*, **114**, 512-528.

Wright IMR, Levene MI, Arthur RA, Martinez D. (1995). A randomised controlled trial of fresh frozen plasma and volume expansion in very low birth weight and sick preterm infants. *British Paediatric Association, 67th Annual Meeting*, **67**, 5

Zipursky A (1999). Prevention of vitamin K deficiency in newborns. *British Journal of Haematology*, **104**, 430-437.

**Keywords :** neonate, developmental haemostasis, thrombosis, bleeding disorders, anticoagulation

**Table 1 :Reference Values for Coagulation Tests in the Healthy Full-term Infant During the First 6 months of Life**

Tests	Day 1 (n)	Day 5 (n)	Day 30 (n)	Day 90 (n)	Day 180 (n)	Adult (n)
PT(s)	13.0 ± 1.43 (61)*	12.4 ± 1.46 (77)*†	11.8 ± 1.25 (67)*†	11.9 ± 1.15 (62)*	12.3 ± 0.79 (47)*	12.4 ± 0.78 (29)
APTT(s)	42.9 ± 5.80 (61)	42.6 ± 8.62 (76)	40.4 ± 7.42 (67)	37.1 ± 6.52 (62)*	35.5 ± 3.71 (47)*	33.5 ± 3.44 (29)
TCT(s)	23.5 ± 2.38 (58)*	23.1 ± 3.07 (64)†	24.3 ± 2.44 (53)*	25.1 ± 2.32 (52)*	25.5 ± 2.86 (41)*	25.0 ± 2.66 (19)
Fibrinogen (g/L)	2.83 ± 0.58 (61)	3.12 ± 0.75 (77)*	2.70 ± 0.54 (67)*	2.43 ± 0.68 (47)*†	2.51 ± 0.68 (47)*†	2.78 ± 0.61 (29)
II(U/ml)	0.48 ± 0.11 (61)	0.63 ± 0.15 (76)	0.68 ± 0.17 (67)	0.75 ± 0.15 (62)	0.88 ± 0.14 (47)	1.08 ± 0.19 (29)
V (U/ml)	0.72 ± 0.18 (61)	0.95 ± 0.25 (76)	0.98 ± 0.18 (67)	0.90 ± 0.21 (62)	0.91 ± 0.18 (47)	1.06 ± 0.22 (29)
VII (U/ml)	0.66 ± 0.19 (60)	0.89 ± 0.27 (75)	0.90 ± 0.24 (67)	0.91 ± 0.26 (62)	0.87 ± 0.20 (47)	1.05 ± 0.19 (29)
VIII (U/ml)	1.00 ± 0.39 (60)*†	0.88 ± 0.33 (75)*†	0.91 ± 0.33 (67)*†	0.79 ± 0.23 (62)*†	0.73 ± 0.18 (47)†	0.99 ± 0.25 (29)
vWF (U/ml)	1.53 ± 0.67 (40)†	1.40 ± 0.57 (43)†	1.28 ± 0.59 (40)†	1.18 ± 0.44 (40)†	1.07 ± 0.45 (46)†	0.92 ± 0.33 (29)†
IX (U/ml)	0.53 ± 0.19 (59)	0.53 ± 0.19 (75)	0.51 ± 0.15 (67)	0.67 ± 0.23 (62)	0.86 ± 0.25 (47)	1.09 ± 0.27 (29)
X (U/ml)	0.40 ± 0.14 (60)	0.49 ± 0.15 (76)	0.59 ± 0.14 (67)	0.71 ± 0.18 (62)	0.78 ± 0.20 (47)	1.06 ± 0.23 (29)
XI (U/ml)	0.38 ± 0.14 (60)	0.55 ± 0.16 (74)	0.53 ± 0.13 (67)	0.69 ± 0.14 (62)	0.86 ± 0.24 (47)	0.97 ± 0.15 (29)
XII (U/ml)	0.53 ± 0.20 (60)	0.47 ± 0.18 (75)	0.49 ± 0.16 (67)	0.67 ± 0.21 (62)	0.77 ± 0.19 (47)	1.08 ± 0.28 (29)
PK (U/ml)	0.37 ± 0.16 (45)	0.48 ± 0.14 (51)	0.57 ± 0.17 (48)	0.73 ± 0.16 (46)	0.86 ± 0.15 (43)	1.12 ± 0.25 (29)
HMW-K (U/ml)	0.54 ± 0.24 (47)	0.74 ± 0.28 (63)	0.77 ± 0.22 (50)*	0.82 ± 0.32 (46)*	0.82 ± 0.23 (48)*	0.92 ± 0.22 (29)
XIIIa (U/ml)	0.79 ± 0.26 (44)	0.94 ± 0.25 (49)*	0.93 ± 0.27 (44)*	1.04 ± 0.34 (44)*	1.04 ± 0.29 (41)*	1.05 ± 0.25 (29)
XIIIb (U/ml)	0.76 ± 0.23 (44)	1.06 ± 0.37 (47)*	1.11 ± 0.35 (45)*	1.16 ± 0.34 (44)*	1.10 ± 0.30 (41)*	0.97 ± 0.20 (29)

**NOTE:** All values expressed as mean +/- 1 SD.

(n) = numbers studied.

All factors except fibrinogen are expressed as units per millilitre where pooled plasma contains 1.0 U/ml.

PK = Prekallikrein, HMW-K = High molecular weight kininogen

\* Values that do not differ statistically from the adult values.

† These measurements are skewed because of a disproportionate number of high values

From Andrew et al 1987 with permission.

**Table 2: Reference Values for the Inhibition of Coagulation in the Healthy Full-term Infant During the First 6 months of Life**

Inhibitors	Day 1 (n)	Day 5 (n)	Day 30 (n)	Day 90 (n)	Day 180 (n)	Adult (n)
AT	0.63 ± 0.12 (58)	0.67 ± 0.13 (74)	0.78 ± 0.15 (66)	0.97 ± 0.12 (60)*	1.04 ± 0.10 (56)*	1.05 ± 0.13 (28)
α <sub>2</sub> -M	1.39 ± 0.22 (54)	1.48 ± 0.25 (73)	1.50 ± 0.22 (61)	1.76 ± 0.25 (55)	1.91 ± 0.21 (55)	0.86 ± 0.17 (29)
C1E-INH	0.72 ± 0.18 (59)	0.90 ± 0.15 (76)*	0.89 ± 0.21 (63)	1.15 ± 0.22 (55)	1.41 ± 0.26 (55)	1.01 ± 0.15 (29)
α <sub>2</sub> -AT	0.93 ± 0.22 (57)*	0.89 ± 0.20 (75)*	0.52 ± 0.13 (51)	0.72 ± 0.15 (56)	0.77 ± 0.15 (55)	0.93 ± 0.19 (29)
HCII	0.43 ± 0.25 (56)	0.48 ± 0.24 (72)	0.47 ± 0.20 (58)	0.72 ± 0.37 (58)	1.20 ± 0.35 (55)	0.96 ± 0.15 (29)
Protein C	0.35 ± 0.09 (41)	0.42 ± 0.11 (44)	0.43 ± 0.11 (43)	0.54 ± 0.13 (44)	0.59 ± 0.11 (52)	0.96 ± 0.16 (28)
Protein S	0.36 ± 0.12 (40)	0.50 ± 0.14 (48)	0.63 ± 0.15 (41)	0.86 ± 0.16 (46)*	0.87 ± 0.16 (49)*	0.92 ± 0.16 (29)

**NOTE:** All values are expressed in units per millilitre as the mean ± 1 SD. (n) is number tested.

\* Values that do not differ statistically from the adult values.

Abbreviations . AT:antithrombin. α<sub>2</sub>-M:α<sub>2</sub>-macroglobulin. C1E-INH: C1 esterase inhibitor. α<sub>1</sub>-AT: α<sub>1</sub>-antithrombin. HC-II: Heparin Cofactor II.

From Andrew et al 1987 with permission.

**Table 3: Reference Values for Coagulation Tests in Healthy Premature Infants (30 to 36 Weeks Gestation) during First 6 Months of life**

Tests	Day 1		Day 5		Day 30		Day 90		Day 180		Adult	
	M	B	M	B	M	B	M	B	M	B	M	B
PT(s)	13.0	(10.6-16.2)*	12.5	(10.0-15.3)*†	11.8	(10.0-13.6)*	12.3	(10.0-14.6)*	12.5	(10.0-15.0)*	12.4	(10.8-13.9)
APTT(s)	53.6	(27.5-79.4)‡	50.5	(26.9-74.1)‡	44.7	(26.9-62.5)	39.5	(28.3-50.7)	37.5	(21.7-53.3)*	33.5	(26.6-40.3)
TCT(s)	24.8	(19.2-30.4)*	24.1	(18.8-29.4)*	24.4	(18.8-29.9)*	25.1	(19.4-30.8)*	25.2	18.9-31.5)*	25.0	(19.7-30.3)
Fibrinogen (g/L)	2.43	(1.50-3.73)*†‡	2.80	(1.60-4.18)*†‡	2.54	(1.50-4.14)*†	2.46	(1.50-3.52)*†	2.28	(1.50=3.60)†	2.78	(1.56-4.00)
II (U/ml)	0.45	(0.20-0.77)†	0.57	(0.29-0.85)‡	0.57	(0.36-0.95)†‡	0.68	(0.30-1.06)	0.87	(0.51-1.23)	1.08	(0.70-1.46)
V (U/ml)	0.88	(0.41-1.44)*†‡	1.00	(0.46-1.54)	1.02	(0.48-1.56)	0.99	(0.59-1.39)	1.02	(0.58-1.46)	1.06	(0.62-1.50)
VII (U/ml)	0.67	(0.21-1.13)	0.84	(0.30-1.38)	0.83	(0.21-1.45)	0.87	(0.31-1.43)	0.99	(0.47-1.51)*	1.05	(0.67-1.43)
VIII (U/ml)	1.11	(0.50-2.13)*†	1.15	(0.53-2.05)*†‡	1.11	(0.50-1.99)*†‡	1.06	(0.58-1.88)*†‡	0.99	(0.50-1.87)*†‡	0.99	(0.50-1.49)
VWF (U/ml)	1.36	(0.78-2.10)†	1.33	(0.72-2.19)†	1.36	(0.66-2.16)†	1.12	(0.75-1.84)*†	0.98	(0.54-1.58)*†	0.92	(0.50-1.58)
IX (U/ml)	0.35	(0.19-0.65)†‡	0.42	(0.14-0.74)†‡	0.44	(0.13-0.80)†	0.59	(0.25-0.93)	0.81	(0.50-1.20)†	1.09	(0.55-1.63)
X (U/ml)	0.41	(0.11-0.71)	0.51	(0.19-0.83)	0.56	(0.20-0.92)	0.67	(0.35-0.59)	0.77	(0.35-1.19)	1.06	(0.70-1.52)
XI (U/ml)	0.30	(0.08-0.52)†‡	0.41	(0.13-0.69)‡	0.43	(0.15-0.71)‡	0.59	(0.25-0.93)‡	0.78	(0.46-1.10)	0.97	(0.67-1.27)
XII (U/ml)	0.38	(0.10-0.66)‡	0.39	(0.09-0.69)‡	0.43	(0.11-0.75)	0.61	(0.15-1.07)	0.82	(0.22-1.42)	1.08	(0.52-1.64)
PK (U/ml)	0.33	(0.09-0.57)	0.45	(0.26-0.75)‡	0.59	(0.31-0.87)	0.79	(0.37-1.21)	0.78	(0.40-1.15)	1.12	(0.62-1.62)
HMWK (U/ml)	0.49	(0.09-0.89)	0.62	(0.24-1.00)‡	0.64	(0.16-1.12)‡	0.78	(0.32-1.24)	0.83	(0.41-1.25)*	0.92	(0.50-1.36)
XIIIa (U/ml)	0.70	(0.32-1.08)	1.01	(0.57-1.45)*	0.99	(0.51-1.47)*	1.13	(0.71-1.55)*	1.13	(0.65-1.61)*	1.05	(0.55-1.55)
XIIIb (U/ml)	0.81	(0.35-1.27)	1.10	(0.68-1.58)*	1.07	(0.57-1.57)*	1.21	(0.75-1.67)	1.15	(0.67-1.63)	0.97	(0.57-1.37)

All factors except fibrinogen are expressed as U/ml, where pooled plasma contains 1.0 U/ml.

All values are given as a mean (M) followed by lower and upper boundary encompassing 95% of the population (B).

Between 40 and 96 samples were assayed for each value for newborns

\* Values indistinguishable from those of adults.

† Measurements are skewed owing to a disproportionate number of high values

‡ Values different from those of full-term infants.

From Andrew et al 1988 with permission.

**Table 4 : Reference Values for Inhibitors of Coagulation in Healthy Premature Infants During First 6 Months of life**

Tests	Day 1		Day 5		Day 30		Day 90		Day 180		Adult	
	M	B	M	B	M	B	M	B	M	B	M	B
AT	0.38	(0.14-0.62)‡	0.56	(0.30-0.82)*	0.59	(0.37-0.81)‡	0.83	(0.45-1.21)‡	0.90	(0.52-1.28)‡	1.05	(0.79-1.31)
α <sub>2</sub> -M	1.10	(0.56-1.82)‡†	1.25	(0.71-1.77)*	1.38	(0.72-2.04)	1.80	(1.20-2.6)†	2.09	(1.10-3.21)†	0.86	(0.52-1.20)
C1E-INH	0.65	(0.31-0.99)	0.83	(0.45-1.21)	0.74	(0.40-1.24)†‡	1.14	(0.60-1.68)*	1.40	(0.96-2.04)†	1.01	(0.71-1.31)
α <sub>1</sub> AT	0.90	(0.36-1.44)*	0.94	(0.42-1.46)‡	0.76	(0.38-1.12)‡	0.81	(0.49-1.13)*‡	0.82	(0.48-1.16)*	0.93	(0.55-1.31)
HCII	0.32	(0.00-0.60)‡	0.34	(0.00-0.69)*	0.43	(0.15-0.71)	0.61	(0.20-1.11)†	0.89	(0.45-1.40)*†‡	0.96	(0.66-1.26)
Protein C	0.28	(0.12-0.44)*‡	0.31	(0.11-0.51)*	0.37	(0.15-0.59)‡	0.45	(0.23-0.67)‡	0.57	(0.31-0.83)	0.96	(0.64-1.28)
Protein S	0.26	(0.14-0.38)‡	0.37	(0.13-0.61)*	0.56	(0.22-0.90)	0.76	(0.40-1.12)‡	0.82	(0.44-1.20)	0.92	(0.60-1.24)

All values are expressed in U/ml, where pooled plasma contains 1.0 U/ml. All values are given as a mean (M) followed by lower and upper boundary encompassing 95% of the population (B). Between 40 and 75 samples were assayed for each value for the newborn.

\* Values indistinguishable from those of adults.

† Measurements are skewed owing to a disproportionate number of high values. Lower limit which excludes the lower 2.5% of the population is given (B).

‡ Values different from those of full-term infants.

From Andrew et al 1988 with permission.

**Table 5: Reference Values for the Components of the Fibrinolytic System in Healthy Full-Term Infants During the First 6 Months of Life, Compared to Those in Adults**

Fibrinolytic Component	Day 1 mean (boundary)	Day 5 mean (boundary)	Day 30 mean (boundary)	Day 90 mean (boundary)	Day 180 mean (boundary)	Adults mean (boundary)
Plasminogen (U/ml)	1.95 (1.25-2.65)	2.17 (1.41-2.93)	1.98 (1.26-2.70)	2.48 (1.74-3.22)	3.01 (2.21-3.81)	3.36 (2.48-4.24)
TPA (ng/ml)	9.60 (5.0-18.9)	5.60 (4.0 -10.0)*	4.10 (1.00-6.00)*	2.1 (1.0-5.0)*	2.8 (1.0-6.0)*	4.9 (1.4-8.4)
$\alpha_2$ AP (U/ml)	0.85 (0.55-1.15)	1.00 (0.70-1.30)*	1.00 (0.76-1.40)*	1.08 (0.76-1.40)*	1.11 (0.83-1.39)*	1.02 (0.63-1.35)
PAI (U/ml)	6.40 (2.0-15.1)	2.30 (0.0 -8.10)*	3.40 (0.0 -8.80)*	7.2 (1.0-15.3)	8.1 (6.0-13.0)	3.6 (0.0-11.0)

TPA, tissue plasminogen activator;  $\alpha_2$ AP,  $\alpha_2$ -antiplasmin; PAI, plasminogen activator inhibitor. For  $\alpha_2$ AP, values are expressed as units per millilitre (U/ml), where pooled plasma contains 1.0 U/ml. Plasminogen units are those recommended by the Committee on Thrombolytic Agents. Values for TPA are given as nanograms per millilitre. Values for PAI are given as units per millilitre, where one unit of PAI activity is defined as the amount of PAI that inhibits 1 international unit of human single-chain TPA. All values are given as a mean followed by the lower and upper boundary encompassing 95% of the population (boundary)

\*Values that are indistinguishable from those of the adult.

From Andrew et al 1990b with permission.

**Table 6: Reference Values for the Components of the Fibrinolytic System in Healthy Premature Infants During the First 6 Months of Life, Compared to Those in Adults**

Fibrinolytic Component	Day mean (boundary)	Day 5 mean (boundary)	Day 30 mean (boundary)	Day 90 mean (boundary)	Day 180 mean (boundary)	Adults mean (boundary)
Plasminogen (U/ml)	1.70 (1.12-2.48) <sup>b</sup>	1.91 (1.21-2.61) <sup>b</sup>	1.81 (1.09-2.53)	2.38 (1.58-3.18)	2.75 (1.91-3.59) <sup>b</sup>	3.36 (2.48-4.24)
TPA (ng/ml)	8.48 (3.00-16.70)	3.97 (2.00-6.93) <sup>a</sup>	4.13 (2.00-7.79) <sup>a</sup>	3.31 (2.00-5.07) <sup>a</sup>	3.48 (2.00-5.85) <sup>a</sup>	4.96 (1.46-8.46)
$\alpha_2$ AP (U/ml)	0.78 (0.40-1.16)	0.81 (0.49-1.13) <sup>b</sup>	0.89 (0.55-1.23) <sup>b</sup>	1.06 (0.64-1.48) <sup>a</sup>	1.15 (0.77-1.53)	1.02 (0.68-1.36)
PAI (U/ml)	5.40 (0.0-12.2) <sup>a,b</sup>	2.50 (0.0-7.1) <sup>a</sup>	4.30 (0.0-10.9) <sup>a</sup>	4.80 (1.0-11.8) <sup>a,b</sup>	4.90 (1.0-10.2) <sup>a,b</sup>	3.60 (0.0-11.0)

All values are given as a mean followed by the lower and upper boundary encompassing 95% of the population (boundary)

<sup>a</sup> Values that are indistinguishable from those of an adult.

<sup>b</sup> Values that are different from those of the full-term infant.

From Andrew et al 1990b with permission.

## Appendix . Graded recommendations.

### Grade of recommendation

A (Evidence levels Ia,Ib)	Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.
B (Evidence levels IIa,IIb,III)	Requires availability of well-conducted clinical studies but no randomised clinical trials on the topic of recommendation
C (Evidence level IV )	Requires evidence from expert committee reports or opinions and/or clinical experience of respected authorities; indicates absence of directly applicable studies of good quality

### Levels of evidence

Ia. Meta-analysis of randomised controlled trials. Ib. At least one randomised controlled trial. IIa. At least one well-designed controlled study without randomisation. IIb. At least one other type of well-designed quasi-experimental study. III. Well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case-control studies. IV. Expert committee reports or opinions and/or clinical evidence of respected authorities.
---